logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2018 — ALK+ NSCLC: brigatinib scores in phase 3 ALTA-1L

Phase 3 data show superior PFS vs crizotinib, even in the presence of CNS involvement.